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Abstract
Background Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect 
non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for 
these costs. They rarely specify the effect of health on labor and who gains and who loses money. Social accounting matrix 
(SAM) is an established framework that evaluates public policies with multiple perspectives that could help.
Objectives We evaluated the use of a modified SAM to assess money flows between different economic agents resulting in 
economic transactions following policy changes of medical interventions.
Methods We compared conventional methods of measuring indirect non-medical costs related to rotavirus vaccination in 
the Netherlands with a modified SAM framework. To compare the outcome of each method, we calculated returns on invest-
ment (ROI) as the net amount of money per euro invested in the vaccine. One-way and probabilistic sensitivity analyses were 
carried out for each method, focusing on critical variables with the largest impact on indirect cost estimates.
Results The ROI was higher for the modified SAM (1.33) than for the conventional methods assessing income calculations 
(range − 0.178 to 1.22). Probabilistic sensitivity analyses showed wide distributions in the ROI estimates, with variation in 
the variable impact on the indirect cost results per method selected.
Conclusions In contrast to conventional methods, the SAM approach provides detailed and comprehensive assessments of 
the impact of new interventions on the indirect non-medical costs and the financial interactions between agents, disclosing 
useful information for different stakeholders.
1 Introduction
Health economic evaluations of new medical products are 
normally performed through incremental cost effectiveness 
analysis (CEA) using direct medical costs from a healthcare 
perspective [1–4]. Some countries recommend a societal 
perspective, especially when new technologies may have an 
impact on the economy outside healthcare [5–8]. Evaluat-
ing health economics from a societal perspective has until 
recently been poorly developed. New attempts have been 
made to explore what could be more appropriate when dif-
ferent stakeholders with different value settings assess the 
benefit of a new intervention looking for the impact at the 
individual- or dimension-specific level [9]. These are inter-
esting explorations, but much effort may be required before 
a consensus is reached in the evaluation. This process needs 
to be repeated for every country assessment, as many of 
the value considerations are culturally, and therefore locally, 
defined. Meanwhile, we aim to focus on one specific element 
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that should be assessed in depth if the economic analysis is 
evaluated at the societal level, namely the indirect non-med-
ical costs. It is maybe a narrow focus in the health economic 
assessment overall, but for some diseases and under some 
circumstances this item could be important to scrutinize 
from the perspective of the different stakeholders involved. 
Indirect non-medical costs are here defined as changes in 
the labor input function caused by work reduction or inter-
ruption due to a disease [10–12]. These costs can be evalu-
ated from an individual, an employer and/or a governmental 
perspective. As there is no single recommended approach, 
large variations in indirect non-medical cost estimates are 
reported [13, 14]. In addition, contemporary methods used 
to assess that item often lack the ability to consider more 
than one perspective simultaneously and to describe the 
money flows that occur between economic domains follow-
ing the introduction of a medical intervention, such as the 
impact of a reduction in household income on tax revenues. 
This lack of completeness when evaluating indirect non-
medical costs renders societal CEA evaluation results prone 
to criticism [15].
In public policy there exists an analytical framework that 
can overcome these hurdles, providing multiple perspec-
tives into one analysis and helping understand the money 
flows across different economic agents, the social account-
ing matrix (SAM) [16, 17]. SAMs have been widely used 
in financial econometrics to understand transactions and 
transfers between different economic agents, such as house-
holds, private firms, and governmental bodies, to monitor 
distribution of wealth and poverty at equilibrium [16, 18, 
19].
In this study, we evaluate the benefits of using a modi-
fied SAM framework focused on the distribution of income 
applicable to healthcare by comparing its results with the 
conventional methods applied to estimate indirect non-med-
ical costs using the human capital method. We investigate 
rotavirus (RV) disease as an example to study the impact of 
vaccination in one specific country, the Netherlands, and 
variation attributed to different methods for assessing indi-
rect costs [20–22]. To date, RV vaccination has not been 
implemented by the Dutch health authorities, although it is 
recommended by the World Health Organization, and it is 
in place in several European countries, including Belgium, 
Germany, and the UK [23]. The modified SAM methodol-
ogy may thereby provide policymakers (Ministry of Health 
[MoH] and of Finance [MoF]) a better understanding of the 
effects a new intervention has on money flows that build up 
to changes in indirect non-medical costs.
2  Methods
2.1  Population and Epidemiology Data Describing 
Rotavirus Disease and the Interventions
RV infection is the main cause of diarrheal disease in young 
children and infects almost every child before the age of 
5 years. Several vaccines exist with comparable vaccine 
efficacy. Only two are available in Europe, a two-dose vac-
cine, Rotarix (GlaxoSmithKline, Belgium) and a three-dose 
vaccine, Rotateq (Merck and Co. Inc) [24]. Both vaccines 
are administered within the first 6 months of age [25, 26]. 
Demographic and epidemiological data have been sourced 
from official Dutch statistics and published literature as 
described elsewhere [22] (Table 1). The number of indi-
viduals at risk of infection includes children aged 0–5 years 
old. Most children with RV infection, on average 40% per 
year, recover at home. However, 13% of RV events lead to a 
general practitioner (GP) visit, 1.6% require hospitalization, 
and 0.4% lead to nosocomial infection [27]. These numbers 
are based on an economic model for RV vaccine in the Neth-
erlands [22]. Inclusion of the RV vaccine into the universal 
mass vaccination (UMV) program would reduce the rotavi-
rus disease incidence in children by approximately 65% [27].
2.2  Direct Medical Costs
In our economic models, direct medical costs include medi-
cal visits, hospitalization, nosocomial infections, and vac-
cine costs. In the case of RV UMV, a vaccination coverage 
of 90% and a tender reduction on vaccine costs of 5% were 
assumed [27] (Table 1).
Key Points 
Several methods exist to calculate the changes in the 
labor input function attributable to poor health as a sur-
rogate for indirect non-medical costs within a societal 
perspective of health economic assessment. However, 
conventional methods fail to capture information about 
who gains and who loses upon the change in labor input 
due to illness or a new intervention aimed at treating or 
preventing a disease.
Social Accounting Matrix (SAM) analyzes financial 
relationships between different economic agents and 
assesses the impact of a new intervention at all levels of 
the economy simultaneously (e.g., households, compa-
nies and government).
The analysis of rotavirus vaccination in the Netherlands 
with a modified SAM analysis shows who gets more or 
who gets less upon the introduction of the vaccination, 
adding valuable information for different stakeholders 
and decision makers.
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2.3  Indirect Non‑Medical Costs
Indirect non-medical costs are estimated using the con-
ventional methods and the application of a modified SAM 
method. The methods have the same assumptions for vaccine 
coverage, vaccine efficacy, and days off work due to illness.
Indirect non-medical costs relate to labor input because 
parents caring for children with RV are absent from work. A 
reduction in labor time because of disease that forces people 
to stay at home to care for children may lead to a reduction 
in production for firms [8]. We briefly summarize how the 
labor input function is estimated by the conventional meth-
ods, each utilizing a slightly different calculation method. 
We then describe how that is captured by a modified SAM 
framework.
2.3.1  Conventional Methods
We consider three calculation methods for the conventional 
approach for estimating the change in labor input function 
in the Netherlands. The most commonly used method for 
the estimation relies on gross income, corresponding to the 
classic human capital approach [28, 29]. The argument sup-
porting the choice of gross wages as a marker of labor input 
is that the amount of money given to individuals corresponds 
to the direct compensation for their contribution to the over-
all production.
Alternatively, net income may be used instead of gross 
income [30]. It is an extension of the previous estimate, 
where individuals’ net income is their return on labor 
input. The net income corresponds to the money received 
after deduction of income tax and/or contribution to social 
security.
The adjusted gross income (AGI) accounts for the spe-
cifics of the Dutch social security system, where employed 
individuals are still paid 70% of their wages when off work 
to care for a sick family member [31]. We therefore consider 
that employed individuals only lose 30% of their daily gross 
income for each day spent off work taking care of a sick 
child. Independent contractors, on the other hand, lose 100% 
of their daily gross income [32].
Table 2 summarizes how these data are calculated with 
the input variables (Table 1).
2.3.2  Modified SAM Framework
SAMs are normally used to assess the effect of policies or 
interventions on the overall economy by establishing links 
between the labor market (households) and financial, eco-
nomic, and social policies [33]. The original SAM uses a 
comprehensive and economy-wide database recording data 
on transactions between economic agents of a certain econ-
omy like agriculture or industry. The interest in working with 
SAMs is twofold: it provides data for economic modelling 
(multi-sectorial linear models or the more complex Com-
putable General Equilibrium [CGE] models) and it shows 
a complete but intuitive snapshot of the economy at hand. 
The concept of using SAMs started with Stone [34]; his 
pioneering work on social accounting includes conventions 
that have been used by economic and statistical organiza-
tions. Pyatt and Thorbecke [35] later formalized the concept 
of the SAM and facilitated its use as an economic analysis 
and planning framework. Underlying is the circular flow of 
income, a concept going back to the circular economy pro-
posed by Boulding [36].
The modified SAM framework developed here focuses on 
the distribution of income in vaccinated and unvaccinated 
cohorts and the spending of those likely to be impacted by a 
disease [37]. It explores how RV vaccination of birth cohorts 
in the Netherlands influences the money flows during a time-
frame of 1 year. It results in more complete indirect cost 
estimates with money transfers between the different eco-
nomic agents impacted by the RV disease, the consequences 
on labor force input and on production. We considered the 
following economic stakeholders: households, firms, MoF, 
MoH, health insurance companies (HiC), and vaccine manu-
facturers. Our starting point to select a stakeholder was the 
household being exposed to rotavirus diarrhea in children. 
The working parent is affected by the money received and 
spent. The analysis highlights which other stakeholders 
are impacted when the parent receives or spends money. 
Selected stakeholders are related to the money changing 
hands. The sum of money spent must be equal to the sum of 
money received in this closed system.
Each economic agent appears in both the columns 
and rows of a square matrix as reported in Tables 4 and 
5 describing part of the modified SAM approach. Money 
transfer between two agents is displayed in the correspond-
ing cell. For example, the adjusted gross income paid by 
firms to their employees (households) appears under the col-
umn ‘firms’ and the row ‘households’. The sum over each 
row represents the revenue of the corresponding economic 
agent, while the sum over columns corresponds to their 
expenses. We created two modified SAMs representing the 
money flows with and without RV vaccination, respectively. 
The difference between the two matrices captures to what 
extent the investment in disease prevention generates a ben-
efit to the economy as a whole and per stakeholder type. 
Table 2B gives the equations used to plug in the numbers 
in the matrix calculation presented in the results using the 
input data listed in Table 1.
2.4  Analysis
A decision tree disease and management model has been 
developed and is described in detail elsewhere [22]. The 
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Table 1  Epidemiology and other input data [22]
G&S goods and services, GP general practitioner, m/f male/female, OECD Organisation for Economic Co-operation and Development, RV rota-
virus, VAT value-added tax
a Numbers in brackets indicate values when the vaccine is used
Parameter Code Input value Source Reference
Annual birth cohort Annual_birth_cohort 182,283 Goossens et al., 2008 [27]
Total annual RV  eventsa Total_RV_events 73,456 (40%)a Goossens et al., 2008 [27]
 Staying home Cases_home 45,365 (25%)a Goossens et al., 2008 [27]
 Medical visit Cases_GP 24,343 (13%)a Goossens et al., 2008 [27]
 Hospital Cases_hosp 2940 (1.6%)a Goossens et al., 2008 [27]
 Nosocomial Cases_nos 808 (0.4%)a Goossens et al., 2008 [27]
Vaccine effect overall VE_overall 65% Zorginstituut, 2017
Goossens et al., 2008
[46]
[27] 1-Vaccine effect – medical visit VE_MedV 12%
 1-Vaccine effect – hospitalization VE_Hosp 7%
 1-Vaccine effect – nosocomial VE_Noso 22%
Average days being absent from work Labor_input 5.5 days Calculated
Direct medical costs
 Cost – GP visit Cost_GP €31.8 Kotsopoulos et al., 2019 [22]
 Cost – hospitalization Cost_hosp €2482 Kotsopoulos et al., 2019 [22]
 Cost – nosocomial infection Cost_nos €2253 Kotsopoulos et al., 2019 [22]
 Vaccine cost/course Vaccine_cost €117 Kotsopoulos et al., 2019 [22]
 Vaccine coverage Vac_cov 90% Assumption
 Tender reduction cost Tender_add 5% Assumption
Indirect non-medical costs
 Gross earnings of an employed 25- to 
35-year-old m/f
Gross_earnings_employed €33,900 Central Bureau of Statistics 2018 
(Werkzame Beroepsbevolking)
[47]
 Gross earnings of an independent 
contractor
 25- to 35-year-old m/f
Gross_earnings_independent €32,000 Central Bureau of Statistics 2018 
(Werkzame Beroepsbevolking)
[47]
 Proportion of employed workers 25- 
to 35-year-old m/f
Prop_employed 88% Central Bureau of Statistics 2018 
(Werkzame Beroepsbevolking)
[47]
 Proportion of independent contract 
workers
 25- to 35-year-old m/f
Prop_independent 12% Central Bureau of Statistics 2018 
(Werkzame Beroepsbevolking)
[47]
 Income tax rate Income_tax_rate 40.85% Belastingdienst 2018 (Inkomstenbelast-
ing)
[48]
 Reimbursement employed for absen-
teeism of care
Reimb_employed 70% Rijksoverheid 2018 [49]
 Gross disposable income main bread-
winner < 35 years
Disposable_income 75% Central Bureau of Statistics 2018 (Inko-
mensverdeling)
[50]
 VAT on G&S VAT_rate 21% OECD 2016 [51]
 Annual working days Working_days 232 Calculated (Kotsopoulos et al., 2019) [22]
 Average payment household insur-
ance/year
Insurance_fee €1200 Kotsopoulos et al., 2019 [22]
Firms
 Gross profit before taxes Firm_profit €222,097,000,000 Central Bureau of Statistics 2016 
(national accounts)
[52]
 Total workforce Total_workforce 6,526,000 Central Bureau of Statistics 2016 
(national accounts)
[52]
 Annual profitability per employee Firm_profit/Total_workforce €34,033 Kotsopoulos et al., 2019 [22]
 Corporate tax rate Corporate_tax_rate 20% Belastingdienst 2018 (Winst) [53]
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Table 2  Equations to calculate the indirect cost estimates using the conventional methods (A) and the modified SAM model (B)
Definition Formula
Cost per event (input in Table 4)
Conventional method A
 Direct medical cost/event (Cases_GP*Cost_GP + Cases_hosp*Cost_hosp + Cases_nos*Cost_nos)/(Cases_
GP + Cases_hosp + Cases_nos)
 Average indirect gross income loss/event ((1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days))/(1- 
Reimb_employed) *Prop_employed + Gross_earnings_independent* (labor_input/
working_days) *Prop_independent
 Average indirect adjusted gross income loss/event (1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days) *Prop_
employed + Gross_earnings_independent* (labor_input/working_days) *Prop_inde-
pendent
 Average indirect net income loss/event ((1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days) 
*Prop_employed + Gross_earnings_independent* (labor_input/working_days) 
*Prop_independent)* (1-Income_tax_rate)
SAM model B (no vaccine)
 Average money loss Household–Firms per event (1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days) *Prop_
employed + Gross_earnings_independent* (labor_input/working_days) *Prop_inde-
pendent
 Average money loss Firms–Household per event (((1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days) 
*Prop_employed + Gross_earnings_independent* (labor_input/working_days) 
*Prop_independent)* (1-Income_tax_rate))* disposable income
 Average money loss MoF–Household per event ((1-Reimb_employed) *Gross_earnings_employed *(labor_input/working_days) 
*Income_tax_rate + (1-Reimb_employed) *Gross_earnings_employed *(labor_
input/working_days) (1-Income_tax_rate) *Disposable_income* VAT_rate) 
*Prop_employed + ((Gross_earnings_independent* (labor_input/working_days) 
*Income_tax_rate + Gross_earnings_independent* (labor_input/working_days)*(1-
Income_tax_rate) *Disposable_income* VAT_rate))*Prop_independent
 Average money loss MoF–Firms per event Daily_profitability_per_employee* labor_input* corporate_tax_rate
 Average money loss MoH–HiC per event (Cases_GP*Cost_GP + Cases_hosp*Cost_hosp + Cases_nos*Cost_nos)/(Cases_
GP + Cases_hosp + Cases_nos)
The difference (input in Table 5)
Conventional method A
 Medical cost (MC)
 No  vaccineMC Cases_GP*Cost_GP + Cases_hosp*Cost_hosp + Cases_nos*Cost_nos
 Adjusted cases GP (example) Cases_GP *Vac_cov*VE_MedV + Cases_GP*(1-Vac_cov)
 UMVMC Adjusted_cases_GP*Cost_GP + Adjusted_cases_hosp*Cost_hosp + Adjusted_cases_
nos*Cost_nos
 Cost-savingsMC No  vaccineMC -UMVMC
Gross income (GI)
 Total_RV_events Cases_home + Cases_GP + Cases_hosp + Cases_nos
 Total_adjusted_RV_events Total_RV_events*(Vac_cov*(1-VE_overall) + (1-Vac_cov))
 Total_vaccine_cost Annual_birth_cohort* Vac_cov* Vaccine_cost
 No  vaccineGI Total_RV_events* average indirect gross income loss/event
 UMVGI Total_adjusted_RV_events* average indirect gross income loss/event
 Cost-savingsGI No  vaccineGI -UMVGI
 Total cost-offsetGI Cost-savingsGI + Cost-savingsMC
 Net  savingsGI Total cost-offsetGI – Total_vaccine_cost
 ROIGI Net  savingsGI/Total_vaccine_cost
SAM method B (savings between Vaccine/No Vaccine)
Net earnings ((1-Income_tax_rate)* Gross_earnings_employed)*Prop_employed + ((1-Income_tax_
rate) *Gross_earnings_independent)* Prop_independent
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model is used to assess indirect non-medical costs as a proxy 
for changes in labor input using the different approaches 
described above with a time horizon of 1 year at infection 
equilibrium time. All input parameters and calculation 
methods are provided in Table 1 and 2. In a first step, each 
conventional method is compared with the SAM method 
in terms of average indirect non-medical cost per RV event 
with no vaccination. To this aim, four perspectives were 
combined in the SAM model, namely households, firms, 
MoH, and the HiC. These are closely interrelated in the eval-
uation of labor input and production. In a second step, the 
overall impact of vaccination on annual direct and indirect 
non-medical costs are calculated as the difference between 
total costs with and without vaccination, assuming a new 
steady state of infections has been reached. The results of the 
conventional approaches are compared with the SAM-model 
output, which includes in addition the MoF and the vaccine 
manufacturer among the stakeholders.
Finally, we measured the return on investment (ROI) 
corresponding to the ratio of the net amount of money per 
euro invested in the vaccine [38]. An ROI of 0 indicates that 
the intervention is cost-neutral; a positive ROI shows that 
money is saved, while a negative ROI means that part of the 
invested money is lost.
2.5  Sensitivity Analyses
Indirect cost estimates are derived from different variables 
whose values are associated with uncertainty. To assess the 
robustness of our results, deterministic and probabilistic 
Table 2  (continued)
Definition Formula
 Rota_adjusted_net earnings (((1-Income_tax_rate)* Gross_earnings_employed) -((1-Income_tax_rate)* 
Gross_earnings_employed) *(labor_input/Working_days)* AC)* Prop_
employed + (((1-Income_tax_rate)* Gross_earnings_independent) -(1-Income_tax_
rate)* Gross_earnings_independent* (labor_input/Working_days)) *Prop_independ-
ent
 Household–Firms No_vaccineAGI -  UMVAGI
 Firms–Household [(((Annual_birth_cohort-Total_RV_events)* Net_earnings) +(Total_RV_events 
*Rota_adjusted_net_earnings))*Disposable_income] – [((Annual_birth_cohort-
Total_adjusted_RV_events) *Net_earnings) +(Total_adjusted_RV_events *Rota_
adjusted_net_earnings)) *Disposable_income]
 Loss of income tax/RV  caseE AC*Gross_earnings_employed*(labor_input/Working_days) *(Income_tax_rate)
 Loss of VAT tax/RV  caseE AC*Gross_earnings_employed*(labor_input/Working_days) *(1-Income_tax_rate) 
*Disposable_income*VAT_rate
 Total tax  lossE Loss of income Tax/RV  caseE + Loss of VAT tax/RV  caseE
 MoF–Household [Annual_birth_cohort*((Income_tax_rate*Gross_earnings) + (Net_
earnings*Disposable_income*VAT_rate)) – (Total_RV_events*Total tax 
 lossE*Prop_employed +Total_RV_events*Total tax lossI*Prop_independ-
ent)]- [Annual_birth_cohort*((Income_tax_rate*Gross_earnings) + (Net_
earnings*Disposable_income*VAT_rate)) – (Total_adjusted_RV__events*Total tax 
 lossE*Prop_employed +Total_adjusted_RV_events*Total tax  lossI*Prop_independ-
ent)]
 MoF–Firms [((Annual_birth_cohort* Annual_profitability_per_employee)- (Daily_profitabil-
ity_per_employee *labor_input *Total_RV_events)) *Corporate_tax_rate]- [((Total_
households* Annual_profitability_per_employee)-(Daily_profitability_per_employee 
*labor_input *Total_adjusted_RV_events)) *Corporate_tax_rate]
 MoF–Vaccine producer Total_vaccine_cost* Tender add
 MoH–HiC No  vaccineMC -UMVMC
 HiC–Household Insurance_fee*Annual_birth_cohort- Insurance fee*Annual_birth_cohort
 Vaccine producer–MoH Total_vaccine_cost
 Revenue/Expenditures Sum (Household-Firms; Firms-Household; MoF-Household; MoF-Firms; MoF-Vac-
cine producer; MoH-HiC; HiC-Household; Vaccine producer- MoH)
 Net savings Revenue- Total_vaccine cost
 ROI Net_savings/Total_vaccine_cost
All other abbreviations used in the second column are defined in Table 1 (second column) or in Table 2 (first column)
AGI adjusted gross income, E employed, GP general practitioner, HiC healthcare insurance companies, hosp hospitalization, I independent, MoF 
Ministry of Finance, MoH Ministry of Health, nos nosocomial, prop proportion, ROI return on investment, RV rotavirus, SAM social accounting 
matrix, UMV universal mass vaccination, VAT value-added tax
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sensitivity analyses (PSA) are carried out. These analyses 
permit to identify  parameters with the largest impact on 
the indirect non-medical costs and to visualize and compare 
the distribution of the estimates for each method using the 
ROI as a common measure of comparison. We know from 
our previous SAM analysis that 10 variables are critical in 
measuring the vaccine cost-offset and the economic surplus: 
(1) vaccine price, (2) vaccine coverage, (3) vaccine efficacy, 
(4) the proportion of workers fully employed, (5) number of 
days being absent from work, (6) total number of RV events, 
(7) corporate taxes, (8) reimbursement rate of employees, (9) 
disposable income, and (10) gross income [22]. The range 
of values and distributions used are shown in Table 3. They 
have been assembled based on a round table discussion with 
local experts in the Netherlands after the presentation of the 
previous analysis [22]. For the PSA, 5000 runs of Monte-
Carlo simulations were carried out using @Risk software, 
Palisade 8, 2020.
3  Results
3.1  Indirect Non‑Medical Costs per RV Event
Table 4 is split into two parts. The upper part reports the 
outcomes per conventional method used, while the lower 
part is the result of the SAM modeling exercise. The colored 
cells indicate where the conventional approach coincides 
with the SAM analysis framework, and should reflect the 
same result type.
Using conventional methods, the average indirect non-
medical cost per RV event varies depending on the selected 
method: the lowest estimate is obtained with the net income 
method (€181.09), while the highest is obtained with the 
gross wages (€806.04). When using the AGI estimation, the 
results lie in between the two extremes (€306.16). Direct 
medical costs, including treatment costs, GP visits, and 
hospitalization, are in the same order of magnitude as the 
indirect non-medical costs (€352.13).
In the modified SAM approach (lower part of Table 4), 
each component of the indirect non-medical cost is pre-
sented as a payment between two economic agents. Some 
of these money transfers exactly match those calculated 
with the conventional approaches: the indirect non-medical 
cost due to a wage decrease is shown as a monetary trans-
action from firms to households in the SAM matrix (same 
color code for those cells). It corresponds to the indirect 
non-medical cost estimate obtained with the adjusted gross 
income method. Other values deviate from those obtained 
with conventional methods due to the additional details pro-
vided in the modified SAM. For example, household spend-
ing is in general proportionate to income and thus both MoF 
and private firms will receive less money from households 
in case of work absenteeism. Within the SAM approach, the 
total indirect non-medical cost corresponds to the sum of 
revenue loss perceived by households, firms, and the MoF 
(€758.50), while direct medical costs amount to €352.13, as 
in the conventional methods.
3.2  Total Disease Costs and Impact of Vaccination
Total disease-related costs were estimated by multiplying 
costs per RV event by the total number of RV events. Vac-
cination reduces the number of events per year from 73,456 
to 30,484 events (Table 1), leading to a reduction in direct 
medical costs of approximately 8 million euros (Table 5). 
The reduction in indirect non-medical costs varies depend-
ing on the method used, but indirect non-medical cost sav-
ings can be higher than the cost savings for direct medical 
costs (Table 5).
Table 5 also presents estimated changes in money flow 
upon RV UMV introduction using the modified SAM 
Table 3  List of variables for which the probabilistic sensitivity analysis is performed
m/f male/female, RV rotavirus, Vac_cov vaccination coverage, VE vaccine efficacy
Variable Code Baseline value Distribution value
1 Total annual RV  eventsa Total_RV_events 73,456 Normal (73,456; 6250)
2 Proportion of employed workers 25- to 35-year-old 
m/f
Prop_employed 88% Uniform (88%; − 5%; + 5%; 10 steps)
3 Vaccine cost/course Vaccine_cost €117 Pert (105.3; 117; 120)
4 Vaccine effect overall VE_overall (100–65%) Normal (35%; 3.5%)
5 Average days being absent from work Labor_input 5.5 days Uniform (5.5; 4.6; 6.05)
6 Vaccine coverage Vac_cov 90% Normal (90%; 4%)
7 Gross earnings of an employed 25- to 35-year-old m/f Gross_earnings_employed €33,900 Pert (33,000; 33,900; 34,000)
8 Reimbursement employed for absenteeism of care Reimb_employed (100–70%) Normal (30%; 3%)
9 Gross disposable income main breadwinner < 35 years Disposable_income 75% Pert (70%; 75%; 80%)
10 Corporate tax rate Corporate_tax_rate 20% Pert (18%; 20%; 22%)
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framework (lower part of the table). It provides additional 
details regarding the impact of RV vaccination on revenues 
of each economic agent. The reduction in direct medical 
costs due to RV vaccination is the same as for conventional 
methods and is shown as a monetary transfer between HiC 
and MoH (again, the same color codes are used for the 
cells in the upper and lower part of the table). Both house-
holds and firms see their revenues increased thanks to the 
improved labor input, which translates into higher tax rev-
enues to the MoF. In addition, the MoF receives taxes from 
the vaccine manufacturer. These gains are partially offset 
by vaccine costs, which are paid by the MoH (assuming a 
5% rebate).
The net savings (difference between revenues and vaccine 
costs) is positive for all methods, except for the net income 
method (Table 5). Thus, in general, vaccination costs are 
compensated by higher revenues, thanks to a reduction in 
work absenteeism. To what extent investment into RV pre-
vention is advantageous for the economy can be assessed 
through the ROI; that is, the ratio between the net cost 
savings (total direct and indirect non-medical costs minus 
vaccine costs) and the vaccine costs (the investment). With 
conventional methods, the ROI is positive for all methods, 
except for the net income method. Among the conventional 
methods, the gross income method leads to the highest ROI 
with values of 1.241 and 1.221, respectively. The SAM 
approach yields a higher estimate for ROI (1.33).
3.3  Sensitivity Analyses
In deterministic sensitivity analyses, total number of RV 
events, lost productivity, reimbursement rate of employees, 
and vaccine efficacy appear to have the largest impact on the 
estimated ROI following the conventional methods (Fig. 1). 
With the modified SAM approach, gross income is the single 
most important variable. Changing this parameter to esti-
mated extreme values leads to higher variability in the ROI 
compared with the conventional methods. Changes in gross 
income impact several economic agents (households, firms, 
and MoF), which might explain why ROI is particularly sen-
sitive to this variable following the SAM approach.
In general, methods with a broader perspective such as 
SAM and the gross income method are more sensitive to var-
iations in key parameters, while more focused approaches, 
such as the net income method, show small changes in the 
ROI in the one-way sensitivity analysis and in their distribu-
tions. This is shown in the PSA results: the broadest distri-
bution of estimated ROI values is observed with the SAM 
approach, while the net income and adjusted gross income 
methods exhibit narrow distributions (Fig. 2). Despite this 
high variability, ROI is positive for the majority of the simu-
lations, meaning that there is a high probability of gaining 
money when investing in RV vaccination, except if a narrow 
focus on net income only is considered.
Table 4  Average indirect non-medical cost per RV event using conventional methods and the modified SAM approach
Conventional of Measuring Direct and Indirect Costsa
tceridnItceriDepyttsoC
Method Medical cost Gross income Adjusted gross income Net income 
4321
Cost/Event (€) 352.13 806.04 306.16 181.09
Comment 30% loss for the 88% employed 
100% for independent workers 
No adjustment to disposable 
income of 75% 
Modified SAM Method of Measuring Direct and Indirect Costs (€) 
 Households Firms MoF MoH HiC Revenue 
Households 306.16 306.16 
Firms 135.82 135.82 
MoF 153.59 162.94    316.52 
MoH 352.13 352.13 
HiC 
Expenditure 289.41 469.09   352.13 1,110.63 
a The colors of the cells indicate equivalent output by the conventional methods versus SAM
HiC healthcare insurance companies, MoF ministry of finance, MoH ministry of health, RV rotavirus, SAM Social Accounting Matrix
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4  Discussion
In this study, we estimated the difference in indirect non-
medical costs due to RV events in the absence or presence 
of vaccination in the Netherlands using different perspec-
tives and methods. The net savings and the ROI obtained 
were calculated for each approach and compared with a new 
method using a modified SAM framework. Indirect non-
medical cost estimates of RV events are in the same order 
of magnitude or larger than the direct medical costs, except 
for the net income method, which yielded a much lower esti-
mate. Indirect non-medical cost estimates obtained with the 
SAM method were towards the higher end of values. The 
large range in the estimates illustrates the importance of the 
perspective selected and emphasizes the difficulty in results 
interpretation for decision making. Many authorities across 
the world question the sources, methodology, and interpreta-
tion of data calculated from a societal perspective because 
of the many uncertainties surrounding those indirect cost 
estimates [1, 15]. Under such circumstances, clear defini-
tions and principles on how to measure it are warranted. 
Health technology evaluations typically work with four cost 
baskets: medical healthcare cost (prevention, treatment, hos-
pitalization, medical visits, tests); non-medical health and 
healthcare-related cost (transport, specific food, and sup-
port); medical infrastructural cost (building, head count, 
administration); and non-medical work/activity impacted 
cost (work reduction) [39]. While we can easily quantify 
the first three cost types, the last item poses problems and 
its definition remains vague. We can quantify the number 
of disease events and the days being absent from work [40], 
however analysts lack clear guidance on how to translate this 
number into a monetary value relevant to decision makers.
Broadly speaking, several economic stakeholders could 
be affected by the health condition of a population (indi-
vidual, household, employer, insurance company or gov-
ernment). Current methodological approaches use a gen-
eral denominator across all these economic stakeholders, 
that is, production and production loss. Different surrogate 
markers for production exist for different perspectives in 
isolation, but which one best approximates our overall eco-
nomic functioning remains elusive. It is generally agreed 
Table 5  Difference in direct and indirect non-medical costs at the population level with and without RV UMV
Conventional Methods 
tceridnItceriDepyTtsoC
Method Medical cost Gross income Adjusted gross income Net income 
No vaccine (€) 9,891,613 59,208,769 22,489,204 13,302,364 
UMV (€) 1,892,925 24,571,639 9,333,020 5,520,481 
Cost savings (€)a 7,998,688 34,637,130 13,156,184 7,781,883 
Total cost-offset (€)b 42,635,818 21,154,872 15,780,571 
Net savings (€)c 23,441,418 1,960,472 -3,413,829 
ROId 871.0-201.0122.1
SAM Method: Cost (€) Savings Due to RV Vaccination a
 Household Firms MoF MoH HiC Vaccine Producer Revenues 
Household 13,156,184     13,156,184 
Firms 5,836,412      5,836,412 
MoF 6,599,948 7,001,621    959,720 14,561,289 
HoM -7,998,688  -7,998,688 
CiH
Vaccine Producer    19,194,400   19,194,400 
Expenditures 12,436,360 20,157,805  19,194,400 -7,998,688 959,720 44,749,597 
Net savings (€)c       25,555,197 
ROId 33.1
a Cost savings are calculated as the difference between costs with no RV vaccination and costs with RV vaccination. 
b Total cost-offsets are calculated as the sum of direct and indirect cost savings
c
Net savings are calculated as Total cost-offset - Total vaccine  cost in case of conventional methods and as Expenditures – Total vaccine cost in case of SAM method 
d
 ROIs are calculated as Net savings / Total vaccine cost 
HiC  healthcare insurance companies, MoF  ministry of finance, MoH  ministry of health, RV  rotavirus, UMV  universal mass vaccination
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upon that indirect non-medical costs are important [15, 41, 
42]. The social security system has been developed on that 
need, based on the solidarity principle that sick people need 
medical attention and continued income during the period 
of illness [43]. These indirect non-medical costs are gener-
ally funded through social security and can be vast com-
pared with direct medical costs, but we rarely consider them 
in health economic evaluations. Rather, we use the more 
abstract concept of production loss for historical reasons or 
ease of use. Meanwhile, other economic disciplines, espe-
cially the financial world, are exposed to similar situations 
where a particular event leads to downstream effects outside 
of the economy where the initial event happened. To fol-
low the ramifications and financial consequences over time, 
SAMs, in addition to other overall economic models such as 
CGEs, were developed [44].
We applied an adaptation of the same technique to 
evaluating the economic impact of RV vaccination in the 
Fig. 1  Deterministic sensitivity analyses to assess impact of key parameters on ROI with different methods. Prop proportion, ROI return on 
investment, RV rotavirus, SAM social accounting matrix, Vac_cov vaccination coverage, VE vaccine efficacy
Fig. 2  PSA to assess impact of key parameters on the distribution of ROI estimates with different methods. AGI adjusted gross income, GI gross 
income, NetI net income, PSA probabilistic sensitivity analysis, ROI return on investment, SAM social accounting matrix
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Netherlands at the societal level, focusing on indirect non-
medical costs. Compared with the conventional methods, 
the modified SAM approach includes monetary gains and 
losses due to RV intervention for all economic stakeholders 
simultaneously. Many of the indirect non-medical cost meas-
ures calculated by conventional methods are also included 
in the SAM approach, but the SAM discloses additional 
information about which stakeholders are involved with the 
direction of money transfers. One most revealing item is 
the specific tax payment gained by the MoF through bet-
ter prevention. This is not disclosed using the conventional 
methods of assessments. This is critical when comparing 
treatment versus prevention, as shown in the example of RV 
vaccination, because indirect non-medical costs are in the 
same order of magnitude as direct medical costs [45]. The 
observed economic gain is more important with the SAM 
approach, because all money-flow perspectives are factored 
in.
Because of the interconnectivity between economic 
agents through monetary transactions, changes in input 
parameters may impact multiple elements in the SAM 
framework simultaneously. This translates into large vari-
ability in the total cost estimates, more than typically seen 
with the conventional methods. In the PSA, the modified 
SAM exhibits the widest distribution in ROI values, though 
ROI remains positive in all simulations. One-way sensitiv-
ity analyses highlight that the ROI was mostly affected by 
the gross income in the SAM approach, while conventional 
methods are most sensitive to the total number of RV events, 
lost productivity, vaccine efficacy, and reimbursement rate 
of employees. SAMs may therefore provide a more realis-
tic picture regarding the uncertainty around cost estimates 
because they evaluate all the interactions between the eco-
nomic stakeholders.
One may question why we should use SAM assessment in 
healthcare. SAM is an instrument mainly developed to better 
assess changes in policy on tax income and payment for the 
overall economy of a specific place, over a fixed evaluation 
period. Should the healthcare budget, being around 10–15% 
of the annual governmental budget expenditures, also com-
ply with the rules of SAM evaluations? Would it be more 
helpful for decision makers to realize that prevention helps 
the economy overall and that employers could benefit as well 
in getting this prevention in place, as shown here? We are 
not advocating that SAM should systematically be applied 
within healthcare per se, but for some critical diseases such 
as infectious diseases with good preventative options like 
vaccination or more frequent chronic diseases for which 
management options prevent severe negative outcomes, a 
SAM evaluation can be very supportive in better decision 
making at all levels.
Limitations of the SAM approach versus conventional 
methods include the use of multiple data and data sources 
at different levels of the economy, ranging from household 
to private companies/firms, insurance providers, and the 
healthcare sector. Information to populate SAM models may 
be more accessible in countries with a fully developed health 
insurance landscape. At the same time, these countries may 
benefit the most from the SAM approach, which provides 
a more complete and transparent picture of the effect a 
new intervention has on the overall economy. Today, there 
is no reference for the use of SAMs in health technology 
assessments and this might constitute a significant hurdle 
in adopting this method. By directly comparing the con-
ventional methods and results with the SAM approach, we 
aim to increase the reliability, validity, and awareness of the 
SAM method in the pharmacoeconomic community. Mean-
while, we should keep in mind that SAM evaluations are not 
new but have been widely used in the financial and public 
world [18, 44]. In addition, because the SAM method has 
not previously been applied to the healthcare sector, there 
is no precedent in what constitutes an acceptable ROI in 
that domain. The SAM method yields a higher estimate of 
indirect non-medical costs than the other methods; this dif-
ference is attributed to the fact that in the SAM approach 
all economic ramifications of an intervention and financial 
relationships are included. Therefore, future research should 
be directed towards defining acceptable values for ROI of 
a new intervention from a societal perspective and careful 
consideration should be given to the choice of method for 
calculating changes in the labor input function.
5  Conclusion
A modified SAM approach combines all economic agents 
impacted by a disease and/or a disease intervention into a 
single framework. It provides a complete and transparent 
picture of the impact a new intervention can have on the 
economy, and therefore might be a suitable tool to investi-
gate direct and indirect non-medical costs from a societal 
perspective. In the case of RV vaccination, direct and indi-
rect non-medical costs estimated with the SAM approach are 
in favor of vaccination in the Netherlands. The SAM method 
provides more details regarding the redistribution of money 
flow in the presence of RV vaccination and this level of 
detail might improve confidence in the results and strengthen 
decisions taken by policy makers. However, it does not mean 
that SAM evaluations should replace any other economic 
assessment normally done in healthcare focusing on health 
gain expressed as QALYs. Our approach suggests how to 
better estimate indirect costs with available evaluation meth-
ods that could be readily applied in healthcare, providing 
transparency to different decision makers and creating a bet-
ter dialogue between stakeholders.
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